Scientists Develop Groundbreaking AKTOCYTE Tablets to Enhance Cancer Radiotherapy Outcomes

In landmark collaboration between the Department of Atomic Energy (DAE) and M/s. IDRS Labs Pvt. Ltd. Bengaluru, scientists have unveiled a groundbreaking development in cancer care – AKTOCYTE tablets. This collaborative effort, which involved experts from Bhabha Atomic Research Centre, Mumbai; Tata Memorial Hospital, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai, aimed to revolutionize cancer treatment by minimizing the side effects of radiotherapy.

AKTOCYTE tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant, have demonstrated remarkable results, particularly in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine). Patients treated with AKTOCYTE tablets showcased extraordinary recovery, eliminating the need for surgical removal of the urinary bladder.

The tablets have received approval from the Food Safety and Standards Authority of India (FSSAI), operating under the Ministry of Health & Family Welfare, Government of India. This regulatory clearance underscores the safety and compliance of AKTOCYTE tablets, providing assurance to healthcare professionals and patients regarding its efficacy and quality.

Key Highlights:

1. Remarkable Recovery in Pelvic Cancer Patients: AKTOCYTE tablets have demonstrated exceptional efficacy in pelvic cancer patients undergoing radiotherapy, showcasing significant recovery and eliminating the need for surgical interventions.
2. Versatile Applications: The tablets serve as more than just a supplement. AKTOCYTE is positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, showcasing its versatility in cancer care.
3. Regulatory Approval: The approval by FSSAI underscores the commitment to safety and quality standards, providing healthcare professionals and patients with confidence in the reliability of AKTOCYTE tablets.
4. Market Availability: Anticipated to hit the market in January 2024, AKTOCYTE tablets are poised to become a transformative addition to cancer treatment protocols.

The collaboration between the institutions of DAE and industry has been instrumental in bringing this breakthrough to fruition. The development marks a pivotal moment in the convergence of scientific innovation and practical solutions for cancer care.